Cell-Penetrating Peptide AP Delivers CTLA-4 Into T Cells to Treat Autoimmune Brain Disease
The cysteine-containing cell-penetrating peptide AP delivered CTLA-4 peptide cargo into T cells both in vitro and in vivo, reducing pathogenic Th17 cells and ameliorating experimental autoimmune encephalomyelitis — a model for multiple sclerosis.
Quick Facts
What This Study Found
AP CPP (9 amino acids with one cysteine) delivered EGFP to human T cells and biodistributed to spleen, liver, intestines, and brain after systemic administration. AP-ctCTLA-4 reduced Th17 differentiation in vitro and ameliorated EAE with decreased IL-17A+GM-CSF+ CD4 T cells in vivo.
Key Numbers
9-AA optimal CPP sequence; crossed BBB; reduced IL-17A+ GM-CSF+ CD4 T cells in EAE
How They Did This
In vitro and in vivo study. AP peptide sequence optimization for T cell delivery. Biodistribution after systemic administration. AP-ctCTLA-4 conjugate tested for Th17 suppression in vitro and EAE amelioration in vivo. Flow cytometry for T cell phenotyping.
Why This Research Matters
T cell-targeted drug delivery is a holy grail of immunotherapy. A CPP that delivers regulatory peptides into T cells AND crosses the blood-brain barrier could treat MS and other autoimmune conditions more effectively than current drugs.
The Bigger Picture
Intracellular delivery to specific immune cells represents the next frontier in autoimmune therapy. AP's ability to deliver functional immune checkpoint molecules directly into T cells — including in the brain — opens possibilities far beyond current antibody-based immunotherapies.
What This Study Doesn't Tell Us
Mouse EAE model — human MS is more complex. Systemic AP delivery may have off-target effects in other tissues. CTLA-4 pathway modulation could cause immunosuppression. Long-term safety not assessed. Peptide stability in circulation unknown.
Questions This Raises
- ?Would AP-CTLA-4 be as effective as injectable CTLA-4 antibodies (like abatacept) with fewer systemic side effects?
- ?Can AP deliver other regulatory molecules to T cells for different autoimmune diseases?
- ?Does AP's blood-brain barrier penetration enable CNS-specific immune modulation?
Trust & Context
- Key Stat:
- T cells + BBB penetration AP peptide delivers cargo into T cells AND crosses the blood-brain barrier — enabling direct immune cell modulation in the CNS for autoimmune brain diseases
- Evidence Grade:
- Moderate evidence: combined in vitro and in vivo data with disease model efficacy and biodistribution. EAE model limitations apply.
- Study Age:
- Published 2021. CPP-based T cell delivery platforms continue advancing toward clinical applications.
- Original Title:
- The Cysteine-Containing Cell-Penetrating Peptide AP Enables Efficient Macromolecule Delivery to T Cells and Controls Autoimmune Encephalomyelitis.
- Published In:
- Pharmaceutics, 13(8) (2021)
- Authors:
- Kim, Won-Ju, Kim, Gil-Ran, Cho, Hyun-Jung, Choi, Je-Min
- Database ID:
- RPEP-05498
Evidence Hierarchy
Frequently Asked Questions
Why is delivering drugs to T cells so important?
T cells drive many autoimmune diseases including MS, rheumatoid arthritis, and type 1 diabetes. Delivering regulatory molecules directly inside T cells could suppress the harmful ones specifically without broadly suppressing the entire immune system — reducing infection risk.
Could this treat multiple sclerosis?
In a mouse MS model, AP-CTLA-4 reduced the disease-causing immune cells and improved outcomes. The fact that AP crosses the blood-brain barrier is especially promising because MS involves immune attack in the brain and spinal cord. Human clinical testing would be needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05498APA
Kim, Won-Ju; Kim, Gil-Ran; Cho, Hyun-Jung; Choi, Je-Min. (2021). The Cysteine-Containing Cell-Penetrating Peptide AP Enables Efficient Macromolecule Delivery to T Cells and Controls Autoimmune Encephalomyelitis.. Pharmaceutics, 13(8). https://doi.org/10.3390/pharmaceutics13081134
MLA
Kim, Won-Ju, et al. "The Cysteine-Containing Cell-Penetrating Peptide AP Enables Efficient Macromolecule Delivery to T Cells and Controls Autoimmune Encephalomyelitis.." Pharmaceutics, 2021. https://doi.org/10.3390/pharmaceutics13081134
RethinkPeptides
RethinkPeptides Research Database. "The Cysteine-Containing Cell-Penetrating Peptide AP Enables ..." RPEP-05498. Retrieved from https://rethinkpeptides.com/research/kim-2021-the-cysteinecontaining-cellpenetrating-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.